Radiopharm Theranostics Ltd has released a press release.
Radiopharm Theranostics completes A$70 million placement
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
In the deck
Story so far
Earlier from Radiopharm Theranostics
- Suspension from Quotation
- Radiopharm Receives Strategic Investment for up to A$18 mill
- Half Yearly Report and Accounts
- Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301
- Pilot Study Validates RAD Terbium-161 Radiotherapeutics
Later from Radiopharm Theranostics
- Reinstatement to Quotation
- First patient dosed in Phase 1 therapeutic lung cancer trial
- FDA IND approval for Phase 2b trial in brain metastases
- RAD increases ownership in Radiopharm Ventures to 75%
- RAD 301 shows strong imaging potential in pancreatic cancer
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics